Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer.

Vergati M, Krasniqi E, Monte GD, Riondino S, Vallone D, Guadagni F, Ferroni P, Roselli M.

Curr Med Chem. 2017;24(12):1170-1185. doi: 10.2174/0929867324666170116122915. Review.


Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.

Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L, La Farina F, Valente MG, Vergati M, Guadagni F, Roselli M.

Int J Cancer. 2015 Mar 1;136(5):1234-40. doi: 10.1002/ijc.29076. Epub 2014 Jul 23.


Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy.

Ferroni P, Guadagni F, Laudisi A, Vergati M, Riondino S, Russo A, Davì G, Roselli M.

Oncologist. 2014 May;19(5):562-7. doi: 10.1634/theoncologist.2013-0339. Epub 2014 Apr 7.


Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.

Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2014 Feb;63(2):161-74. Epub 2013 Nov 15.


Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.

Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.

Oncologist. 2013;18(7):821-2. doi: 10.1634/theoncologist.2013-0199. Epub 2013 Jul 11.


Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer.

Vergati M, Della-Morte D, Ferroni P, Cereda V, Tosetto L, La Farina F, Guadagni F, Roselli M.

Rejuvenation Res. 2013 Jun;16(3):224-31. doi: 10.1089/rej.2013.1409.


Impact of chemotherapy on activated protein C-dependent thrombin generation--association with VTE occurrence.

Roselli M, Ferroni P, Riondino S, Mariotti S, Laudisi A, Vergati M, Cavaliere F, Palmirotta R, Guadagni F.

Int J Cancer. 2013 Sep 1;133(5):1253-8. doi: 10.1002/ijc.28104. Epub 2013 Mar 16.


Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.

Huen NY, Pang AL, Tucker JA, Lee TL, Vergati M, Jochems C, Intrivici C, Cereda V, Chan WY, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY.

Int J Cancer. 2013 Jul 15;133(2):373-82. doi: 10.1002/ijc.28026. Epub 2013 Feb 12.


Perianal Paget's disease: a case report and literature review.

Vergati M, Filingeri V, Palmieri G, Roselli M.

Anticancer Res. 2012 Oct;32(10):4461-5. Review.


Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients.

Roselli M, Ferroni P, Portarena I, Riondino S, La Farina F, Formica V, Vergati M, Guadagni F.

Thromb Haemost. 2012 Dec;108(6):1243-5. doi: 10.1160/TH12-06-0418. Epub 2012 Oct 10. No abstract available.


Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.

Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.


Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

Cereda V, Vergati M, Huen NY, di Bari MG, Jochems C, Intrivici C, Gulley JL, Apelian D, Schlom J, Tsang KY.

Vaccine. 2011 Jul 12;29(31):4992-9. doi: 10.1016/j.vaccine.2011.04.101. Epub 2011 May 11.


The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring.

Vergati M, Schlom J, Tsang KY.

J Biomed Biotechnol. 2011;2011:182413. doi: 10.1155/2011/182413. Epub 2011 Jan 20.


Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2011 Feb;60(2):197-206. doi: 10.1007/s00262-010-0927-9. Epub 2010 Oct 26.


Strategies for cancer vaccine development.

Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY.

J Biomed Biotechnol. 2010;2010. pii: 596432. doi: 10.1155/2010/596432. Epub 2010 Jul 11. Review.


Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.

Cancer Immunol Immunother. 2010 May;59(5):663-74. doi: 10.1007/s00262-009-0782-8. Epub 2009 Nov 5.


Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.

Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P.

Mol Cell Endocrinol. 2007 Jan 29;264(1-2):44-9. Epub 2006 Nov 9.


Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.

Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio AS, Zhang J, Cuzzocrea S, Graziani G.

FASEB J. 2006 Aug;20(10):1709-11. Epub 2006 Jun 29.


Corticotropin-releasing hormone receptor-1 in human endometrial cancer.

Graziani G, Ferrandina G, Pozzoli G, Vergati M, Muzi A, Legge F, Tentori L, Scambia G, Navarra P.

Oncol Rep. 2006 Feb;15(2):375-9.


Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.

Tentori L, Leonetti C, Scarsella M, Muzi A, Vergati M, Forini O, Lacal PM, Ruffini F, Gold B, Li W, Zhang J, Graziani G.

Eur J Cancer. 2005 Dec;41(18):2948-57. Epub 2005 Nov 8.


Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs.

Tentori L, Vergati M, Muzi A, Levati L, Ruffini F, Forini O, Vernole P, Lacal PM, Graziani G.

Int J Oncol. 2005 Aug;27(2):525-35.


Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.

Tentori L, Leonetti C, Scarsella M, Vergati M, Xu W, Calvin D, Morgan L, Tang Z, Woznizk K, Alemu C, Hoover R, Lapidus R, Zhang J, Graziani G.

Int J Oncol. 2005 Feb;26(2):415-22.


N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity.

Tentori L, Forini O, Fossile E, Muzi A, Vergati M, Portarena I, Amici C, Gold B, Graziani G.

Mol Pharmacol. 2005 Feb;67(2):572-81. Epub 2004 Nov 17.


Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G.

Clin Cancer Res. 2003 Nov 1;9(14):5370-9.


Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells.

Graziani G, Tentori L, Portarena I, Vergati M, Navarra P.

Endocrinology. 2003 Jul;144(7):2822-8.


Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.

Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G.

Mol Pharmacol. 2003 Jan;63(1):192-202.


Supplemental Content

Loading ...
Support Center